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Abstract
Background—Human papillomavirus (HPV) can cause oropharyngeal and anogenital cancers 
among men who have sex with men (MSM). In 2011, the Advisory Committee on Immunization 
Practices (ACIP) extended HPV vaccine recommendations to males through age 21 and MSM 
through age 26. Because of this distinction, vaccination for some MSM might rely on sexual 
behavior disclosure to health care providers. Receipt of ≥1 HPV vaccination among MSM aged 
18–26 in National HIV Behavioral Surveillance (NHBS) was 4.9% in 2011. We evaluated HPV 
vaccine coverage and associated factors among MSM in 2014.
Setting—Twenty US metropolitan statistical areas in 2014.
Methods—Coverage was calculated as percentage of MSM self-reporting ≥1 HPV vaccination. 
Adjusted prevalence ratios were calculated from Poisson regression models to estimate 
associations of demographic and behavioral characteristics with HPV vaccination.
Results—Among 2892 MSM aged 18–26 years, HPV vaccine coverage was 17.2%. Overall, 
2326 (80.4%) reported a health care visit within 12 months, and 2095 (72.4%) disclosed MSM 
attraction or behavior to a health care provider. Factors associated with vaccination included self-
reported HIV infection; having a health care visit within 12 months, health insurance, or a usual 
place of care; and disclosing MSM attraction or behavior to a health care provider.
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Conclusions—Since the 2011 recommendation for vaccination of males, HPV vaccine coverage 
among MSM increased, but remains low. Most MSM reported a recent health care visit and 
disclosed sexual behavior, indicating opportunities for vaccination. Potential strategies for 
increasing MSM coverage include improving access to recommended care, and offering education 
for providers and patients.
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INTRODUCTION
Human papillomavirus, or HPV, is the most common sexually transmitted infection in the 
United States, with an estimated 14 million persons newly infected annually.1 Persistent 
infection can cause genital warts and cervical, anogenital, and oropharyngeal cancers. HPV 
is estimated to have an annual direct medical cost of 1.8 billion dollars.2 Among all US men, 
incidence of HPV-associated anal and oropharyngeal cancers has been increasing over the 
past 15 years.3 Among men who have sex with men (MSM), both incidence and prevalence 
of anal HPV infection are high.4 Anal cancer rates are also high in this population, similar to 
the incidence of cervical cancer before the introduction of national cervical cancer screening 
programs.5 HIV-positive MSM have an anal cancer incidence that is 9 times that of HIV-
negative MSM.5 These diseases are considered largely preventable with prophylactic HPV 
vaccination.
Quadrivalent HPV vaccine (4vHPV), which protects against 4 types of HPV causing most 
HPV-related disease, was first licensed in 2006, initially for use in females. In 2009, after 
licensure for males, the Advisory Committee on Immunization Practices (ACIP) made a 
permissive recommendation, stating that the vaccine may be used for males. In late 2011, a 
routine recommendation was made for males at age 11 or 12, through age 21 for all males, 
and through age 26 for MSM and for immunocompromised persons, including those with 
HIV infection.6 In 2015, recommendations for use of the 9-valent vaccine (9vHPV) were 
made for the same populations.7
Several studies have evaluated HPV vaccine coverage among MSM since the routine 
recommendation for males in 2011. Baseline coverage among US MSM was calculated 
using 2011 data from National HIV Behavioral Surveillance (NHBS), since most of these 
data were collected before the routine ACIP recommendation for males. The analysis 
showed that 4.9% of 3221 MSM aged 18–26 years reported receiving ≥1 dose of HPV 
vaccine, with 13.4% coverage among 224 HIV-positive MSM.8 Four studies of online survey 
data have published point estimates of HPV vaccine coverage among MSM aged 18–26 
years after the 2011 policy. In December 2011, coverage for ≥1 dose of HPV vaccine was 
6.8% among 1457 MSM using a website for men seeking other men.9 Among 1098 
participants aged 18–26 years in a large online survey for US MSM at-risk for HIV in 2012, 
14.0% reported receiving ≥1 dose of HPV vaccine.10 An online survey conducted in late 
2013 found that ≥1 dose coverage was 13.1% among 428 men aged 18–26 years who self-
identified as gay or bisexual.11 In 2014–2015, ≥1 dose coverage was 20.8% among 336 aged 
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18–26 years young men using a smartphone dating application for MSM and identifying as 
gay, bisexual, queer, or questioning or report ever having anal sex with a male.12 These 
studies, however, were relatively small, conducted primarily among internet-using MSM, 
and are not directly comparable to each other. More recent survey data from NHBS can be 
directly compared with previous NHBS vaccination coverage estimates to assess changes 
over time in HPV vaccine coverage in this population across the United States.
The objective of this study was to evaluate ≥1 HPV vaccine coverage and associated factors 
among a large population of vaccine-eligible MSM aged 18 years and older in the United 
States in 2014, 3 years after HPV vaccine was recommended routinely for males.
MATERIALS AND METHODS
NHBS is a multicity surveillance system conducted among groups considered at high risk 
for HIV infection in the United States. MSM are surveyed every third year–long cycle. The 
surveillance system is designed to monitor HIV seroprevalence, risk behaviors, testing, 
treatment, and prevention and in 2014, was conducted in 20 metropolitan statistical areas 
(MSAs) with a high HIV/AIDS burden. Detailed methods have been reported 
elsewhere,13,14 as have characteristics of the overall sample.15 NHBS uses venue-based 
sampling methods that are briefly described here. First, staff identified venues frequented by 
MSM (eg, bars, clubs, gyms, parks, street locations, and social organizations) and days and 
times when men frequented those venues. Venues in which at least 50% of men attending 
were MSM were eligible for inclusion. Site staff determined venue eligibility through 
secondary data review, interviews, focus groups, or observations. Second, venues and 
corresponding day/time periods were selected randomly for recruitment events. Third, staff 
members systematically approached men at recruitment events to screen for eligibility (aged 
≥18 years, reside in MSA surveyed, assigned male sex at birth and currently identify as 
male, report ever had sex with another man, and able to complete the interview in English or 
Spanish). Interviews were conducted by trained interviewers using a standardized, 
anonymous questionnaire about demographics, sexual behavior, HPV vaccination history, 
HIV or other sexually transmitted disease (STD) testing, and other health care use, and 
offered a nominal incentive, with amounts determined locally. Responses from the fourth 
MSM cycle, conducted from January through December 2014, are used in this analysis. 
NHBS activities were approved by local institutional review boards in each participating 
city. NHBS activities were determined to be research in which the Centers for Disease 
Control and Prevention (CDC) were not directly engaged and, therefore, did not require 
separate review by the CDC institutional review board.
The percentage of all MSM self-reporting ≥1 dose of HPV vaccine was evaluated; further 
analyses were limited to MSM aged 18–26 years, within the target age range for HPV 
vaccination. Bacterial sexually transmitted infections were defined as syphilis, chlamydia, or 
gonorrhea. We calculated descriptive frequencies and performed bivariate analyses using 
Pearson χ2 tests to assess associations between self-reported receipt of HPV vaccine and 
demographic characteristics, behavioral risk factors, and other sexual health characteristics. 
In addition, we assessed health care use, including recent health care visits and disclosure of 
same-sex sexual attraction or behavior to a health care provider. Prevalence ratios with 95% 
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confidence intervals (CIs) were calculated from separate Poisson regression models with 
generalized estimating equations to estimate associations of each demographic and 
behavioral characteristic with HPV vaccination. All models were clustered on venue-based 
sampling recruitment event. Adjusted prevalence ratios (aPRs) are presented for the 
associations between select health care-associated covariates and HPV vaccination. Separate 
models were built for each association. Initially, each model was adjusted for age, race, 
education, insurance status, census region, self-reported HIV status, and sexual identity; 
backward elimination was then used to reduce models, based on an alpha of 0.05, until only 
significant covariates remained in the models. When characteristics were reported, results 
from the South and Territories census regions were combined because of standard NHBS 
reporting procedures; however, each census region was considered separately in all models 
presented. Statistical analyses were performed using SAS software, version 9.3 (SAS 
Institute, Cary, NC).
RESULTS
Of 10,369 consenting NHBS participants with valid surveys, 10,161 (98.0%) provided a 
response when asked about HPV vaccination. Of those, a total of 860 (8.5%) reported ever 
receiving ≥1 dose of HPV vaccine (Table 1). The proportion of MSM reporting any HPV 
vaccination was lower among older age groups. Of 1654 MSM who were HIV positive by 
self-report, 228 (13.2%) reported receiving ≥1 dose of HPV vaccine. In every age group, 
HIV-positive MSM had higher vaccination coverage than HIV-negative MSM.
Among young MSM aged 18–26 years, there were 2982 consenting NHBS participants with 
valid surveys, and 2892 (97.0%) provided a response about HPV vaccination. Among these 
men, 497 (17.2%) reported ever receiving ≥1 dose of HPV vaccine. Of 277 self-reported 
HIV-positive MSM, 103 (37.2%) reported ever receiving ≥1 dose of HPV vaccine; 242 
(87%) reported having a usual place of care, 266 (96%) reported that they have visited a 
health care provider within 12 months, and 262 (95%) reported disclosure of same-sex 
sexual attraction or behavior to a health care provider.
In bivariate analysis among MSM aged 18–26 years, HPV vaccine coverage was 
significantly associated with several demographic characteristics, health care use, and sexual 
behaviors (Table 2). Coverage was higher among the younger age group, men aged 18–21 
years, compared with those aged 22–26 years. Coverage was also higher among non-
Hispanic white MSM, those with at least some college education, and those residing in the 
Northeast or West regions of the United States. Having health insurance, a usual place of 
health care, a health care visit within the last 12 months, and having been tested or 
diagnosed with an STD were all associated with higher reported HPV vaccine coverage. 
There was a trend toward higher coverage among men reporting more sex partners in the 
previous 12 months.
In multivariable analysis, reporting a positive HIV test (aPR 2.60; CI: 2.19 to 3.08), a 
physician visit to healthcare provider in the past 12 months (aPR 2.35; CI: 1.69 to 3.28), any 
health insurance (aPR 1.69; CI: 1.35 to 2.12), a usual place of care (aPR 1.56; CI: 1.24 to 
1.98), and disclosure of same-sex sexual attraction or behavior to a health care provider 
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(aPR 1.42; CI: 1.14 to 1.76) were associated with receipt of ≥1 dose of HPV vaccine (Table 
3).
Most young men reported opportunities for vaccination. Of all young vaccine-eligible MSM, 
2142 (74.6%) reported having some form of health insurance. In addition, 2326 (80.4%) 
reported visiting a health care provider within the past 12 months and 2095 (72.4%) reported 
disclosing male attraction or behavior to their health care provider.
DISCUSSION
Three years after a national recommendation for HPV vaccination of men, HPV vaccine 
coverage among MSM aged 18–26 years was 17.2%. Coverage among HIV-positive MSM 
in this age range was 37.2%, and 15.1% among those who did not report a positive HIV test. 
Most young MSM had a recent health care visit and disclosed sexual behavior to their health 
care provider, suggesting opportunities for vaccination. Access to health care was 
significantly associated with vaccination.
Compared with a similar analysis using NHBS data in 2011,8 coverage increased 12.3 
percentage points, from 4.9% to 17.2% among all young vaccine-eligible MSM, and 23.8 
percentage points, from 13.4% to 37.2%, among those who report being HIV-positive. 
Coverage in our sample was higher than that among young men aged 19–26 in the general 
US population, according to an estimate from the National Health Interview Survey, which 
found that 8.2% reported ≥1 dose of HPV vaccine in 2014.16 Of note, among boys aged 13–
17 years, an estimated 49.8% received ≥1 dose of HPV vaccine in 2015, according to the 
National Immunization Survey-Teen.17 As coverage increases in adolescents, coverage will 
increase over time as men vaccinated as adolescents age into the older groups, such as the 
MSM surveyed in NHBS.
In this analysis, the highest vaccine coverage was reported among young HIV-positive 
MSM. This group is at particularly high risk for HPV-related diseases5; higher coverage 
might represent increased access to routine preventive or sexual health care and/or health 
care professionals who are more likely to adhere to current immunization guidelines for this 
population. CDC’s STD Treatment Guidelines18 specify elements of recommended care for 
all sexually active MSM, including testing for HIV and other STDs, and vaccination against 
hepatitis A and B and HPV.
HPV vaccines are ideally administered before exposure to HPV,19–21 and studies of incident 
infections demonstrate that first HPV infection usually occurs within a few years of 
becoming sexually active.22 However, a recent study among 922 vaccine-eligible gay, 
bisexual, and other MSM aged 18–26 years in 2 US cities demonstrated that while 90.9% of 
HIV-positive young MSM and 62.9% of other MSM were seropositive for any 4vHPV types, 
only 29.5% of HIV-positive MSM and 8.5% of other MSM were seropositive for all four 
4vHPV types of HPV.23 These findings suggest that sexually active young MSM can benefit 
from vaccination.
Our analysis is subject to several limitations. Survey results are self-reported, and may be 
subject to social desirability bias or recall error. Given the anonymous nature of the survey, 
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receipt of vaccination could not be confirmed with medical records. In addition, total 
number of doses of HPV vaccine was not assessed, so completion of the vaccine series could 
not be evaluated. Finally, venue-attending MSM in large MSAs may not be representative of 
all MSM in the MSAs, or of all US MSM.
HPV vaccination coverage has increased among US MSM since ACIP’s routine 
recommendation for males in 2011 but remains low. It is important to offer HPV vaccine for 
all unvaccinated MSM through age 26 years. This study demonstrated that most young 
MSM regularly seek health care and disclose sexual behavior to their health care providers. 
Given these opportunities to provide recommended health care, potential strategies for 
increasing HPV vaccine coverage include strengthening education for health care providers 
and patients about current vaccination policies and national recommendations, and 
improving access to recommended care among this at-risk population.
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TABLE 1
MSM Reporting ≥1 Dose of HPV Vaccine, by Age and Self-Reported HIV Status—National HIV Behavioral 
Surveillance, United States, 2014
Age Group,
yr
All
Participants, N
Received ≥1 Dose of HPV 
Vaccine,
Among All Participants, n (%)
Self-Reported Positive HIV 
Test,
Among All Participants, n 
(%)
Received ≥1 Dose of HPV Vaccine,
Among Participants Reporting
a Positive HIV Test, n (%)
18–26 2892 497 (17.2) 277 (9.6) 103 (37.2)
27–30 1581 164 (10.4) 208 (13.2) 39 (18.8)
31–40 2426 111 (4.6) 393 (16.2) 46 (11.7)
>40 3262 88 (2.7) 776 (23.8) 40 (5.2)
Total 10,161 860 (8.5) 1654 (16.3) 228 (13.8)
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TABLE 2
HPV Vaccine Coverage Among Young Men Aged 18–26 Years Who Have Sex With Men, by Characteristic—
National HIV Behavioral Surveillance, United States, 2014
Characteristic
Participants,
N
Reported ≥1
Dose of HPV
Vaccine, n (%)
Prevalence Ratio
(95% Confidence
Interval)
Total 2892 497 (17.2)
Age group, yr
  18–21 683 139 (20.4) 1.26 (1.05 to 1.50)
  22–26 2209 358 (16.2) Ref
Race/ethnicity
  White 761 151 (19.8) Ref
  Black 972 165 (17.0) 0.86 (0.69 to 1.07)
  Hispanic/Latino* 883 123 (13.9) 0.70 (0.56 to 0.88)
  Other† 260 56 (21.5) 1.09 (0.83 to 1.41)
Education
  Up to high school 1058 149 (14.1) Ref
  Some college or higher 1834 348 (19.0) 1.35 (1.11 to 1.63)
Sexual identity
  Homosexual/Gay 2271 413 (18.2) Ref
  Bisexual 550 73 (13.3) 0.73 (0.57 to 0.93)
  Heterosexual/straight 56 6 (10.7) 0.59 (0.28 to 1.23)
Census Region
  South and Territories 1216 125 (10.3) Ref
  Northeast 779 206 (26.4) 2.57 (2.07 to 3.19)
  West 601 127 (21.1) 2.06 (1.62 to 2.61)
  Midwest 296 39 (13.2) 1.28 (0.88 to 1.87)
Current health insurance
  None 729 74 (10.2) Ref
  Any 2142 420 (19.6) 1.93 (1.53 to 2.44)
Usual place of care
  None 696 68 (9.8) Ref
  Any 2195 429 (19.5) 2.00 (1.59 to 2.52)
Usual place of care‡
  Hospital ED 435 51 (11.7) Ref
  Clinic or health center 753 158 (21.0) 1.79 (1.34 to 2.39)
  Doctor’s office or HMO 1249 249 (19.9) 1.70 (1.29 to 2.24)
  Other 63 9 (14.3) 1.22 (0.62 to 2.36)
Visited HCP in past 12 months
  No 566 33 (5.8) Ref
  Yes 2326 464 (20.0) 3.42 (2.45 to 4.78)
Disclosed same-sex sexual attraction or behavior to a HCP
  No 797 87 (10.9) Ref
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Characteristic
Participants,
N
Reported ≥1
Dose of HPV
Vaccine, n (%)
Prevalence Ratio
(95% Confidence
Interval)
  Yes 2095 410 (19.6) 1.80 (1.45 to 2.23)
Tested for HIV in past 12 months
  No 789 104 (13.2) Ref
  Yes 2081 389 (18.7) 1.42 (1.17 to 1.72)
HIV test result, self-reported
  Negative or unknown 2615 394 (15.1) Ref
  Positive 277 103 (37.2) 2.45 (2.08 to 2.93)
Tested for a bacterial STD in past 12 months
  No 1231 115 (9.3) Ref
  Yes 1656 381 (23.0) 2.46 (1.99 to 3.04)
Told had a bacterial STD in past 12 months
  No 2424 395 (16.3) Ref
  Yes 468 102 (21.8) 1.34 (1.10 to 1.63)
Ever told had genital warts
  No 2787 472 (16.9) Ref
  Yes 105 25 (23.8) 1.41 (0.98 to 2.01)
Number sex partners in past 12 months§
  1 420 58 (13.8) Ref
  2–3 882 147 (16.7) 1.19 (0.91 to 1.56)
  4–5 534 94 (17.6) 1.26 (0.93 to 1.69)
  >5 980 184 (18.8) 1.34 (1.03 to 1.75)
*
Persons identifying as Hispanic or Latino can be of any race.
†
Includes Asian, Pacific Islander, American Indian, other race, or multiple races.
‡Among participants reporting ≥1 usual place of care.
§Among participants reporting ≥1 sex partner in past 12 months.
ED, Emergency Department; HCP, Health care provider; HMO, Health maintenance organization.
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TABLE 3
Adjusted Prevalence Ratios for Self-Reported Receipt of HPV Vaccine Among Young Men Aged 18–26 Years 
Who Have Sex With Men—National HIV Behavioral Surveillance, United States, 2014
Characteristic
Adjusted Prevalence Ratio, (95%
Confidence Interval)
Self-reported HIV test result
  Negative or unknown Ref
  Positive 2.60 (2.19 to 3.08)*
Visited health care provider in past 12 months
  No Ref
  Yes 2.35 (1.69 to 3.28)†
Health insurance
  None Ref
  Any 1.69 (1.35 to 2.12)†
Usual place of care
  None Ref
  Any 1.56 (1.24 to 1.98)†
Disclosed same-sex sexual attraction or behavior to a health care provider
  No Ref
  Yes 1.42 (1.14 to 1.76)†
*Separate models built for each association; the final model adjusted for age, education, insurance status, and region.
†Separate models built for each association; the final model adjusted for age, education, insurance status, region, and self-reported HIV test result.
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